HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

High Calcium, Vitamin D Intake Does Not Reduce Breast Cancer Risk – JNCI

This article was originally published in The Tan Sheet

Executive Summary

High calcium and vitamin D supplementation was not found to reduce the risk of invasive breast cancer in postmenopausal women in a Journal of the National Cancer Institute study

You may also be interested in...



“Breakthrough” Vitamin D Study Shows Reduced Cancer Risk

A study finding calcium plus vitamin D reduces the risk for developing cancer in postmenopausal women is a "breakthrough," according to the Council for Responsible Nutrition

Vitamin D Studies May Lend Support To Increased Upper Intake Level – Shao

Findings from two separate studies that suggest an increase in vitamin D intake can cut cancer risk by at least half may help "corral enough support" to look at increasing the upper intake level (UL)for vitamin D, according to Andrew Shao, Ph.D., VP scientific and regulatory affairs for the Council for Responsible Nutrition

HBW Executive Decisions: Perrigo Americas, Nutraceutical International Helm Changes, ABC Farnsworth Award, More

Myos Rens hires Eric LeGrand as special advisor for sports nutrition; Perrigo Consumer Americas chief Jeff Needham will be succeeded by Rich Sorota; Nutraceutical International appoints Monty Sharma to replace Chad Clawson at the helm; American Botanical Council’s Farnsworth Award goes to Rachel Mata; and Herbalife’s John Agwunobi will be chairman as well as CEO.

Topics

UsernamePublicRestriction

Register

RS137521

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel